These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 2020764

  • 1. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

  • 2. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
    Zeman EM, Lemmon MJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
    [Abstract] [Full Text] [Related]

  • 3. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
    Brown JM, Lemmon MJ.
    Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
    [Abstract] [Full Text] [Related]

  • 4. Pre- and post-irradiation radiosensitization by SR 4233.
    Zeman EM, Brown JM.
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
    [Abstract] [Full Text] [Related]

  • 5. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
    Zeman EM, Brown JM.
    Int J Radiat Biol; 1991 Jan; 59(1):117-31. PubMed ID: 1671059
    [Abstract] [Full Text] [Related]

  • 6. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
    Brown JM, Lemmon MJ.
    Cancer Res; 1990 Dec 15; 50(24):7745-9. PubMed ID: 2253217
    [Abstract] [Full Text] [Related]

  • 7. Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin.
    Sun JR, Brown JM.
    Radiat Res; 1993 Feb 15; 133(2):252-6. PubMed ID: 8438067
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM, Hirst VK, Lemmon MJ, Brown JM.
    Radiother Oncol; 1988 Jul 15; 12(3):209-18. PubMed ID: 3175048
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ, Menke D, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jan 01; 28(1):145-50. PubMed ID: 8270435
    [Abstract] [Full Text] [Related]

  • 10. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan 01; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 11. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
    Xu P, Huang JM, Ren Y, Zha X, Deng BF, Wu JH, Lang JY.
    Chin J Cancer; 2010 Feb 01; 29(2):126-30. PubMed ID: 20109337
    [Abstract] [Full Text] [Related]

  • 12. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun 01; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 13. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M, Stevens G.
    Melanoma Res; 1998 Dec 01; 8(6):510-5. PubMed ID: 9918413
    [Abstract] [Full Text] [Related]

  • 14. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI, Brown JM.
    Br J Cancer; 1992 Dec 01; 66(6):1053-8. PubMed ID: 1457345
    [Abstract] [Full Text] [Related]

  • 16. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 17. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Jan 15; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
    Stern S, Guichard M.
    Radiother Oncol; 1996 Nov 15; 41(2):143-9. PubMed ID: 9004358
    [Abstract] [Full Text] [Related]

  • 19. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M.
    Br J Cancer Suppl; 1996 Jul 15; 27():S61-4. PubMed ID: 8763848
    [Abstract] [Full Text] [Related]

  • 20. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
    Herman TS, Teicher BA, Coleman CN.
    Cancer Res; 1990 Aug 15; 50(16):5055-9. PubMed ID: 2379171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.